Skip to content

CaHMB L-arginine-glutamine blended drinks (Abound (TM)) for amyotrophic lateral sclerosis patients and sarcopenia improvement effect by drinking.

CaHMB L-arginine-glutamine blended drinks (Abound (TM)) for amyotrophic lateral sclerosis patients and sarcopenia improvement effect by drinking. - The sarcopenia improvement effect by Abound (TM) drinking against ALS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000019111
Enrollment
20
Registered
2015-10-01
Start date
2015-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis

Interventions

Abound(TM) 1,Take one pack twice a day in the moring and evening 2,Drinking was dissolved in water 240 ~ 300ml 3,Before meals, after meals does not matter 4,12 weeks

Sponsors

National Hospital Organization Takasaki General Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.He was diagnosed with amyotrophic lateral sclerosis diagnostic criteria (El Escorial criteria revised version) in accordance amyotrophic lateral sclerosis, cases that have been made notice to the patient himself. 2.Patients that can be oral drinking 3.Patient consent is obtained in writing with respect to participation in the study.

Exclusion criteria

Exclusion criteria: 1,Patients are managed breathing by the ventilator. 2,oral drinking difficult patient. 3,Patients with a history of side effects caused by Abound(TM). 4,Patients unable intention display in the self- 5,Patients who are judged to be inappropriate as a research subject.

Design outcomes

Primary

MeasureTime frame
1.Improvement of muscle mass 2.Respiratory function test values, improvement of grip strength

Countries

Japan

Contacts

Public ContactMitsuyasu Kanai

National Hospital Organization Takasaki General Medical Center Division of Neurology

kanai@takasaki-hosp.jp027-322-5901

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026